ATLANTA, GA – – (Globe Newswire – April 14, 2023) – – Holzer & Holzer, LLC is investigating whether Sarepta Therapeutics, Inc. (“Sarepta Therapeutics” or the “Company”) (NASDAQ: SRPT) complied with federal securities laws.  On March 16, 2023, Sarepta Therapeutics announced that “at its late cycle meeting for the SRP-9001 (delandistrogene moxeparvovec) biologics license application (BLA), the U.S. Food and Drug Administration’s Office of Therapeutics (OTP) has determined that an advisory committee meeting will be held for SRP-9001 in advance of the May 29, 2023 regulatory action date.” Following this announcement, the price of the Company’s stock dropped.

If you purchased Sarepta Therapeutics stock and suffered a loss on that investment, you are encouraged to contact Marshall Dees, Esq. at  mdees@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at https://holzerlaw.com/case/sarepta-therapeutics/ to discuss your legal rights.